Dermapharm Holding SE (DMP) Stock Statistics & Valuation Metrics

Dermapharm Holding SE has a market cap or net worth of CHF2.12B. The enterprise value is CHF3.23B.

Dermapharm Holding SE has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Dermapharm Holding SE’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 7.97%.

The current PE Ratio of Dermapharm Holding SE is 17.3. Dermapharm Holding SE’s PEG ratio is 0.96.

In the last 12 months, Dermapharm Holding SE had revenue of 1.16B and earned 132.41M in profits. Earnings per share was 2.46.

In the last 12 months, operating cash flow was 242.22M and capital expenditures -43.89M, giving a free cash flow of 198.33M billion.

Dermapharm Holding SE pays an annual dividend of ―, resulting in a dividend yield of ―

Dermapharm Holding SE upcoming earnings date is Aug 25, 2026, TBA (Confirmed).

Dermapharm Holding SE as a current ratio of 2.05, with Debt / Equity ratio of 140.69%

In the past 12 months, Dermapharm Holding SE has paid 52.16M in taxes.

Dermapharm Holding SE EV to EBITDA ratio is 9.44, with an EV/FCF ratio of 21.29.

Dermapharm Holding SE has CHF225.93M in cash and marketable securities with CHF1.04B in debt, giving a net cash position of -CHF813.53M billion.

Gross margin is 42.74%, with operating margin of 19.03%, and net profit margin of 11.37%.

The average price target for Dermapharm Holding SE is CHF47.85, which is 11.43% higher than the current price. The consensus rating is Moderate Buy